Screener
Crinetics Pharmaceuticals CRNX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| CURRENT ASSETS | ||
| Cash and cash equivalents | $114,341 | $101,536 |
| Investment securities, amortized cost of $1,178,076 at March 31, 2026 and $924,317 at December 31, 2025 | 1,176,965 | 926,353 |
| Trade accounts receivable, net | 5,683 | 592 |
| Inventory | 3,064 | 2,022 |
| Prepaid expenses and other current assets | 22,361 | 17,839 |
| Total current assets | 1,322,414 | 1,048,342 |
| Property and equipment, net | 13,497 | 14,296 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's accounts receivable?
- Crinetics Pharmaceuticals (CRNX) reported accounts receivable of $5.68M in Q1 2026.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Crinetics Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude